ERS 2026: tozorakimab's groundbreaking exacerbation reduction sets a new bar in COPD

At ERS 2026, AstraZeneca presented full results from its Phase III OBERON and TITANIA trials of its IL-33 inhibitor, tozorakimab. The focus of this latest data presentation was the drug’s efficacy in reducing moderate and severe exacerbations among COPD patients who continued to experience exacerbations despite inhaled standard-of-care therapy. OBERON and TITANIA were double-blind, placebo-controlled Phase III trials enrolling just over 2,300 patients with a history of two or more moderate or one or more severe COPD exacerbations in the prior 12 months. Credit: Jo Panuwat D via Shutterstock.com. On September 8, at the European Respiratory Society (ERS) Congress in…

Source: Clinical Trials Arena